Episode 411: An Encouraging Clinical Trial for Progressive MS with Jason Tardio

Back in Episode #401, we reported promising results from a Phase 2 clinical trial for vidofludimus calcium and its impact on progressive MS. This therapy is being developed by Immunic Therapeutics, and this week, Jason Tardio, Immunic's President and Chief Operating Officer, joins me to share some of the specifics of that clinical trial. 

 

Jason will also shed light on why Immunic believes that vidofludimus calcium goes beyond merely slowing disability, potentially offering vital neuroprotection for MS patients, making it a potential game-changer.

We're also sharing the encouraging results from a study that focused on the efficacy of neural stem cell transplantation as a remyelination therapy.

We'll tell you about a study in the U.K. that measured disability progression among people with MS five years after undergoing autologous hematopoietic stem cell transplantation (aHSCT).

You'll learn about an AI tool that can predict whether someone living with MS is likely to experience progression independent of relapse activity (PIRA) with a high degree of accuracy.

We'll tell you where you can catch the International Progressive MS Alliance webcast featuring a panel of experts discussing the future role of digital tools in MS research.

We'll explain how one of the less publicized aspects of the One Big Beautiful Bill Act will impact future MS care.

And Crush MS is less than two weeks away! We're sharing all the details!

We have a lot to talk about! Are you ready for RealTalk MS??!

---

This Week: Encouraging results from a clinical trial for progressive MS.  :22

How a less-publicized aspect of the One Big Beautiful Bill Act will impact future MS patient care 1:18

A study looked at the efficacy of neural stem cell transplantation as a remyelination therapy  4:31

A study in the U.K. analyzed disability progression among people with MS five years after receiving autologous hematopoietic stem cell therapy (aHSCT)   7:42

Can AI accurately predict who will experience progression independent of relapse activity (PIRA)?  10:45

Don't miss the International Progressive MS Alliance webcast featuring experts discussing the future role of digital tools in MS research  12:40

Are you ready to support MS research while spending the afternoon in a Napa Valley vineyard? Get all the details to attend Crush MS  13:45

Jason Tardio, President and Chief Operating Officer of Immunic Therapeutics, discusses the recent Phase 2 clinical trial for vidofludimus calcium as a therapy for progressive MS  15:03

Share this episode  30:03

Have you downloaded the free RealTalk MS app?  30:23

---

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/411

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or